BPIFA1 and ovarian cancer: Building on such work, our previous study proposed LUNX mRNA and LUNX protein to be a specific diagnostic marker and a novel candidate therapeutic target for NSCLC, respectively, because no detectable expression of LUNX has been found in other tumors such as hepatocellular carcinoma or ovarian cancer [10, 42].